SAN DIEGO--(BUSINESS WIRE)--Jan. 17, 2012--      Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results      for fourth quarter and fiscal year 2011 following the close of market on      Tuesday, January 31, 2012.    
      On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay      Flatley, President and Chief Executive Officer, Christian Henry, Senior      Vice President and General Manager, Life Sciences, and Marc Stapley,      Senior Vice President and Chief Financial Officer, will host a      conference call with analysts, investors, and other interested parties      to discuss financial and operating results.    
      Conference Call Details    
      The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern      Time) on Tuesday, January 31, 2012. Interested parties may listen to the      call by dialing 888.680.0892 (passcode: 84484335), or if outside North      America, by dialing +1.617.213.4858 (passcode: 84484335). Individuals      may access the live teleconference in the Investor Relations section of      Illumina's web site under the “Company” tab at www.illumina.com.    
      A replay of the conference call will be available from 4:30pm Pacific      Time (7:30pm Eastern Time) on January 31, 2012 through February 7, 2012      by dialing 888.286.8010 (passcode: 25712497), or if outside North      America, by dialing +1.617.801.6888 (passcode: 25712497).    
      About Illumina    
      Illumina (www.illumina.com)      is a leading developer, manufacturer, and marketer of life science tools      and integrated systems for the analysis of genetic variation and      function. We provide innovative sequencing and array-based solutions for      genotyping, copy number variation analysis, methylation studies, gene      expression profiling, and low-multiplex analysis of DNA, RNA and      protein. We also provide tools and services that are fueling advances in      consumer genomics and diagnostics. Our technology and products      accelerate genetic analysis research and its application, paving the way      for molecular medicine and ultimately transforming healthcare.    
    

Source: Illumina, Inc.
      Illumina, Inc.
Investors:
Kevin Williams, MD,      Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Laura      Trotter, Public Relations
858-882-6822
pr@illumina.com